new england journal medicine published another study catie group time testing second generation aka sga atypical antipsychotic medications patients alzheimer disease let start quoting authors conclusion abstract adverse effects offset advantages efficacy atypical antipsychotic drugs treatment psychosis aggression agitation patients alzheimer disease olanzapine zyprexa risperidone risperdal quetiapine seroquel showed significant advantage group combining three medications one group placebo efficacy primary outcome measure clinical global impressions improvement scale patients olanzapine rated least minimal improvement compared quetiapine risperidone placebo comparing olanzapine placebo difference statistically significant barely p authors report effect size differences across cgi i neuropsychiatric inventory brief psychiatric rating scale appear ish range according mental calculations based reported means standard deviations suggesting modest improvement drug versus placebo another important measure discontinuation treatment overall significant difference placebo medication frequently treatment discontinued clinicians safety weeks olanzapine risperidone groups gained body weight compared placebo patients medications resulted significantly greater increase body mass index compared placebo olanzapine risperidone significantly likely cause extrapyramidal symptoms compared placebo remember one reason sgas supposedly superior older antipsychotic meds sgas would cause extrapyramidal symptoms low rate hmmm thank nimh funding study bad news continues flow second generation antipsychotics link study abstract feel free read atypical antipsychotics